文献速递急性肾损伤慢性肾脏病

髓系盐皮质激素受体通过巨噬细胞IL-4受体信号调控肾损伤后炎症与纤维化

The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling.
PubMed 文献 · Kidney Int · 2018-03-13

该研究在小鼠双侧肾缺血再灌注模型中,发现新型非甾体盐皮质激素受体拮抗剂finerenone或选择性髓系盐皮质激素受体敲除可预防后续慢性肾功能不全和纤维化,与巨噬细胞M2抗炎标志物表达增加及炎症性CD11b+、F4/80+、Ly6Chigh巨噬细胞减少相关,并促进IL-4受体表达和活化,该保护作用在大白猪临床前模型中也得到验证。

要点

  • finerenone或髓系MR敲除可减轻小鼠肾缺血再灌注后慢性功能障碍和纤维化
  • 保护作用伴随巨噬细胞M2抗炎标志物增加和炎症性Ly6Chigh巨噬细胞减少
  • MR抑制促进IL-4受体表达和活化,推动巨噬细胞向M2表型极化

核心结论

  • 髓系盐皮质激素受体通过巨噬细胞IL-4受体信号调控肾损伤后炎症和纤维化,支持MR拮抗剂用于预防AKI向CKD转化。

研究设计与样本

  • 小鼠双侧肾缺血再灌注模型,使用finerenone或选择性髓系MR敲除,并在大白猪临床前模型中验证。

主要发现

  • finerenone或髓系MR敲除保护小鼠免于缺血再灌注后慢性功能障碍和纤维化。
  • 保护作用伴随巨噬细胞M2抗炎标志物表达增加和炎症性CD11b+、F4/80+、Ly6Chigh巨噬细胞减少。
  • MR抑制促进全肾和分离巨噬细胞中IL-4受体表达和活化,促进M2极化。
  • 长期保护作用在大白猪临床前模型中也得到验证。

临床怎么用

  • 提示MR拮抗剂可能用于临床预防急性肾损伤向慢性肾脏病转化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute kidney injury induced by ischemia/reperfusion is an independent risk factor for chronic kidney disease. Macrophage recruitment plays an essential role during the injury and repair phases after an ischemic episode in the kidney. Here we show that the novel non-steroidal mineralocorticoid receptor antagonist finerenone or selective myeloid mineralocorticoid receptor ablation protects against subsequent chronic dysfunction and fibrosis induced by an episode of bilateral kidney ischemia/reperfusion in mice. This protection was associated with increased expression of M2-antiinflamatory markers in macrophages from finerenone-treated or myeloid mineralocorticoid receptor-deficient mice. Moreover, the inflammatory population of CD11b+, F4/80+, Ly6Chigh macrophages was also reduced. Mineralocorticoid receptor inhibition promoted increased IL-4 receptor expression and activation in the whole kidney and in isolated macrophages, thereby facilitating macrophage polarization to an M2 phenotype. The long-term protection conferred by mineralocorticoid receptor antagonism was also translated to the Large White pig pre-clinical model. Thus, our studies support the rationale for using mineralocorticoid receptor antagonists in clinical practice to prevent transition of acute kidney injury to chronic kidney disease.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Barrera-Chimal J, Estrela GR, Lechner SM, et al. The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling. Kidney Int. 2018. PMID: 29548765. doi:10.1016/j.kint.2017.12.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。